Samsung Bioepis Reports the Initiation of the P-I Trial Evaluation of SB27 (biosimilar, pembrolizumab) for the Treatment of Lung Cancer

Shots: 

• The company received the MHLW’s approval to initiate a P-I clinical trial for the bioequivalence evaluation of SB27 as compared to Keytruda (pembrolizumab) 

• The P-I clinical trial evaluates the safety, efficacy & immunogenicity of SB27 vs Keytruda in patients with Stage II-IIIA NSCLC following complete resection & adjuvant Platinum-based CT 

• Keytruda is a PD-1-blocking antibody approved for the treatment of various indications incl. NSCLC 

Ref: Samsung Bioepis| Image: Samsung Bioepis | Press Release

Related News:- Coherus BioSciences Launches an On Body Injector for the Administration of Udenyca (biosimiolar, pegfilgrastim) to Treat Non-Myeloid Malignancies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com